| Enrolling By Invitation | ATTRACT-52: Primary Care Cardiac Amyloidosis Screening in Ordu, Turkey NCT07238426 | Kotyora Family Medicine Health Management and Education Association | — |
| Recruiting | The Eplontersen Pregnancy and Lactation Outcomes Study NCT07205666 | AstraZeneca | — |
| Not Yet Recruiting | Retrospective Identification of Scintigraphic Cardiac Amyloidosis (RISCA) NCT06921408 | University Hospital, Lille | — |
| Recruiting | Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers NCT06563895 | Eidos Therapeutics, a BridgeBio company | Phase 3 |
| Recruiting | Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis NCT06465810 | AstraZeneca | — |
| Active Not Recruiting | Myocardial Effects in Patients With ATTRv With Polyneuropathy Treated With Patisiran or Vutrisiran NCT05873868 | Rennes University Hospital | — |
| Recruiting | Phenotyping and Characterization of wtATTR-CM (TRACE 1) NCT06291805 | Steen Hvitfeldt Poulsen | — |
| Completed | Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis NCT04899180 | Mayo Clinic | EARLY_Phase 1 |
| Recruiting | New Biomarkers and Plasma Prothrombotic Potential in Cardiac Transthyretin Amyloidosis NCT06345235 | John Paul II Hospital, Krakow | — |
| Recruiting | Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis NCT05758493 | Oregon Health and Science University | Phase 2 |
| Active Not Recruiting | Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisira NCT05023889 | Austin Neuromuscular Center | EARLY_Phase 1 |
| Withdrawn | Evaluation of a Claims-based Algorithm for the Identification of Transthyretin-mediated Amyloidosis (ATTR) Amy NCT04569903 | Yale University | EARLY_Phase 1 |
| Completed | Evuzamitide in PET/CT to Measure Potential Therapeutic Response in ATTR NCT05635045 | Columbia University | Phase 2 |
| Completed | Study of Cerebral MRI Anomalies in Mutated Transthyretin Amyloidosis Patients NCT05075798 | Centre Hospitalier Universitaire de Nīmes | — |
| Unknown | The Effect of Tafamidis on Transthyretin Stabilization, Safety, Tolerability and Efficacy in Transthyretin Amy NCT04963985 | Peking University Third Hospital | Phase 4 |
| Recruiting | Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF NCT05577819 | Massachusetts General Hospital | N/A |
| Terminated | Transthyretin Cardiac Amyloidosis in Patients With Idiopathic Carpal Tunnel Syndrome Referred for Release Surg NCT04611204 | University Hospital, Toulouse | — |
| Unknown | ATTR-Cardiomyopathy Stabilization Following Tafamidis Therapy NCT04513600 | The Christ Hospital | — |
| Unknown | Systemic Transthyretin Amyloidosis: Carpal Tunnel Syndrome in a Portuguese Population NCT05409833 | Universidade do Porto | — |
| Unknown | The Regional Scintigraphic DPD Uptake in Cardiac Transthyretin Amyloidosis. NCT05814380 | Katarzyna Holcman | — |
| Completed | Prevalence of wtATTR-CM After Carpal Tunnel Release Surgery NCT04276220 | Steen Hvitfeldt Poulsen | N/A |
| Unknown | Patient-Reported Outcome Measures in Wild-Type and Variant Cardiac Transthyretin Amyloidosis NCT04563286 | University of Messina | — |
| Completed | Cardiac Amyloidosis Screening at Trigger Finger Release NCT03886155 | The Cleveland Clinic | — |
| Completed | Screening for Systemic Amyloidosis Via the Ligamentum Flavum NCT03923920 | The Cleveland Clinic | — |
| Completed | Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progressi NCT03862807 | Alnylam Pharmaceuticals | Phase 3 |
| Completed | Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy NCT03860935 | Eidos Therapeutics, a BridgeBio company | Phase 3 |
| Completed | HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amy NCT03759379 | Alnylam Pharmaceuticals | Phase 3 |
| Enrolling By Invitation | PL_GNT01_ISR_Grant 53234273 NCT06714019 | National Institute of Cardiology, Warsaw, Poland | — |
| Completed | Short-term Effects of TOLCAPONE on Transthyretin Stability in Subjects With Leptomeningeal TTR Amyloidosis (AT NCT03591757 | Boston University | EARLY_Phase 1 |
| Completed | Expanding the Biomarkers in Familial Amyloid Neuropathy: MRI and Motor Unit Estimation by Electrophysiological NCT03588468 | Assistance Publique Hopitaux De Marseille | N/A |
| Withdrawn | Biomarker for Transthyretin-Related Familial Amyloidotic Polyneuropathy (BioTRAP) NCT02713880 | CENTOGENE GmbH Rostock | — |
| Completed | Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis NCT03431896 | The Cleveland Clinic | — |
| Completed | Positron Emission Tomography / Magnetic Resonance Imaging in Aortic Stenosis NCT03352089 | University of Edinburgh | — |
| Completed | Assessment of the Prevalence of TTR Amyloid Neuropathy in a Population of Patients With Neuropathy of Unknown NCT03190577 | Nantes University Hospital | N/A |
| Completed | TRAMmoniTTR Study Genetic Screening of an At-risk Population for hATTR and Monitoring of TTR Positive Subjects NCT03237494 | CENTOGENE GmbH Rostock | — |
| Completed | Carpal Tunnel Syndrome and Amyloid Cardiomyopathy NCT02792790 | The Cleveland Clinic | — |
| Completed | Safety and Efficacy Study of Doxycycline/UrsoDeoxyCholicAcid on Disease Progression in ATTR Amyloidosis NCT02016365 | Umeå University | Phase 2 |
| Completed | Safety, Efficacy and Pharmacokinetics of Doxycycline Plus Tauroursodeoxycholic Acid in Transthyretin Amyloidos NCT01171859 | Fondazione IRCCS Policlinico San Matteo di Pavia | Phase 2 |
| Completed | Transthyretin Amyloidosis Outcome Survey (THAOS) NCT00628745 | Pfizer | — |